Autolus Therapeutics plc ADR (NASDAQ:AUTL) has a beta value of 2.06 and has seen 1.88 million shares traded in the last trading session. The company, currently valued at $375.23M, closed the last trade at $1.41 per share which meant it lost -$0.14 on the day or -9.03% during that session. The AUTL stock price is -347.52% off its 52-week high price of $6.31 and -7.8% below the 52-week low of $1.52. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.54 million shares traded. The 3-month trading volume is 1.24 million shares.
The consensus among analysts is that Autolus Therapeutics plc ADR (AUTL) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
Autolus Therapeutics plc ADR (NASDAQ:AUTL) trade information
Sporting -9.03% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the AUTL stock price touched $1.41 or saw a rise of 17.06%. Year-to-date, Autolus Therapeutics plc ADR shares have moved -40.00%, while the 5-day performance has seen it change -12.96%. Over the past 30 days, the shares of Autolus Therapeutics plc ADR (NASDAQ:AUTL) have changed -19.43%. Short interest in the company has seen 9.13 million shares shorted with days to cover at 7.04.
Wall Street analysts have a consensus price target for the stock at $7.6, which means that the shares’ value could jump 81.45% from current levels. The projected low price target is $7.6 while the price target rests at a high of $7.6. In that case, then, we find that the current price level is -439.01% off the targeted high while a plunge would see the stock gain -439.01% from current levels.
Autolus Therapeutics plc ADR (AUTL) estimates and forecasts
The company’s shares have lost -61.16% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 21.36% over the past 5 years. Earnings growth for 2025 is a modest -4.85% while over the next 5 years, the company’s earnings are expected to increase by 23.49%.
AUTL Dividends
Autolus Therapeutics plc ADR is expected to release its next earnings report on 2025-Mar-19 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Autolus Therapeutics plc ADR (NASDAQ:AUTL)’s Major holders
Insiders own 18.09% of the company shares, while shares held by institutions stand at 85.97% with a share float percentage of 104.96%. Investors are also buoyed by the number of investors in a company, with Autolus Therapeutics plc ADR having a total of 143.0 institutions that hold shares in the company. The top two institutional holders are SYNCONA PORTFOLIO LTD with over 21.35 million shares worth more than $74.29 million. As of 2024-06-30, SYNCONA PORTFOLIO LTD held 8.0243% of shares outstanding.
The other major institutional holder is BLACKSTONE INC., with the holding of over 20.49 million shares as of 2024-06-30. The firm’s total holdings are worth over $71.29 million and represent 7.7006% of shares outstanding.
